Tumor receptors

Tumor receptors is a broad, collective term used to describe a wide variety of proteins expressed on the surface or within the cytoplasm and nucleus of cancer cells that facilitate malignant transformation and progression. These receptors, including receptor tyrosine kinases (RTKs), G protein-coupled receptors (GPCRs), and nuclear receptors, often undergo overexpression or gain-of-function mutations that drive autonomous cell growth, survival, and metastasis [Source: PubMed, PMC4049335]. Because these proteins are frequently more abundant or uniquely altered in tumor cells compared to normal physiological states, they serve as the primary foundation for targeted oncology therapies [Source: StatPearls, NBK542211]. Therapeutic agents such as monoclonal antibodies and small-molecule inhibitors are designed to bind these receptors, thereby blocking downstream signaling pathways like MAPK/ERK or PI3K/Akt/mTOR [Source: NIH, NCI Dictionary]. While targeting these receptors has revolutionized cancer treatment, challenges such as acquired resistance and off-target toxicities in healthy tissues remain significant clinical hurdles. Ultimately, the term "Tumor receptors" is a functional category rather than a specific molecular target, encompassing hundreds of distinct entities like EGFR, HER2, and the Estrogen Receptor.

Other names

Cancer cell receptorsTumor-associated receptorsOncogenic receptorsMalignancy-associated receptors

Tumor receptors are targeted through several distinct mechanisms: monoclonal antibodies can block ligand binding or induce antibody-dependent cellular cytotoxicity (ADCC), while small-molecule inhibitors typically penetrate the cell membrane to inhibit intracellular kinase domains [Source: StatPearls, NBK542211]. Additionally, some therapies involve modulating nuclear receptors to alter gene transcription or using receptors as docking sites for drug-conjugates [Source: NIH, NCI Dictionary].